
Titan Biotech Ltd is Rated Buy by MarketsMOJO
2026-11-14 10:10:28Titan Biotech Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 07 November 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 14 November 2026, providing investors with the most up-to-date insight into the stock’s performance and outlook.
Read MoreTitan Biotech Gains 2.30%: 3 Key Factors Driving the Week’s Mixed Momentum
2026-11-07 15:06:13Key Events This Week Nov 2: Stock opens at Rs.339.85, closes sharply lower at Rs.325.60 (-4.19%) amid rating downgrade Nov 3: Technical momentum shifts to mildly bullish; stock recovers slightly to Rs.328.30 (+0.83%) Nov 6: Q2 FY27 results released showing strong profit growth but expensive valuation; stock surges 5.19% to Rs.347.65 Week OpenRs.339.85 Week Close</div...
Read MoreTitan Biotech Gains 4.30%: 3 Key Factors Driving the Weekly Rally
2026-10-31 16:00:37Key Events This Week 26 Oct: Downgrade to Hold amid mixed technical and valuation signals 27 Oct: Technical momentum shifts to mildly bullish with price rebound 28 Oct: Technical upgrade to Buy as momentum indicators improve 30 Oct: Week closes at Rs.339.85, up 4.30% for the week Week OpenRs.325.85 Week Close<div clas...
Read More
Titan Biotech Ltd Technical Momentum Shifts Signal Bullish Outlook
2026-10-28 08:03:53Titan Biotech Ltd, a micro-cap player in the specialty chemicals sector, has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend. This change is underpinned by a combination of moving averages, MACD, and other key technical indicators, signalling renewed investor interest and potential upside in the stock’s price trajectory.
Read More
Titan Biotech Ltd Downgraded to Hold Amid Mixed Technical and Valuation Signals
2026-10-26 08:09:37Titan Biotech Ltd, a micro-cap player in the Specialty Chemicals sector, has seen its investment rating downgraded from Buy to Hold as of 23 October 2026. This revision reflects a nuanced assessment across four key parameters: quality, valuation, financial trend, and technicals. Despite robust recent financial performance and impressive long-term returns, evolving technical indicators and valuation metrics have tempered enthusiasm among analysts.
Read More
Titan Biotech Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-10-26 08:01:55Titan Biotech Ltd, a micro-cap player in the Specialty Chemicals sector, has experienced a notable shift in its technical momentum, moving from a bullish to a mildly bullish trend. Despite a recent downgrade in its Mojo Grade from Buy to Hold, the stock’s price action and technical indicators present a nuanced picture of its near-term prospects, warranting a detailed analysis for investors navigating this evolving landscape.
Read MoreTitan Biotech Gains 0.10% Amid Bullish Technical Upgrade and Market Volatility
2026-10-24 16:00:05Key Events This Week Oct 19: Stock rises 0.38% despite Sensex fall Oct 21: Technical upgrade and 2.69% price jump Oct 22: Buy rating upgrade announced Oct 23: Profit-taking leads to 2.36% decline Week OpenRs.325.52 Week CloseRs.325.85+0.10% ...
Read More
Titan Biotech Ltd Upgraded to Buy on Strong Technical and Financial Performance
2026-10-22 08:15:02Titan Biotech Ltd, a micro-cap player in the Specialty Chemicals sector, has seen its investment rating upgraded from Hold to Buy by MarketsMOJO as of 21 Oct 2026. This upgrade reflects a confluence of improved technical indicators, robust financial trends, solid quality metrics, and a valuation that, while premium, is justified by the company’s recent performance and growth prospects.
Read More
Titan Biotech Ltd Technical Momentum Shifts Signal Bullish Outlook
2026-10-22 08:04:50Titan Biotech Ltd has exhibited a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish trend, supported by a combination of moving averages, Bollinger Bands, and MACD signals. This micro-cap specialty chemicals company’s recent price action and technical indicators suggest a strengthening market sentiment, positioning it favourably against broader benchmarks such as the Sensex.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
06-Nov-2026 | Source : BSENewspaper publication for Unaudited Financial Result (Standalone & Consolidated) for the quarter and half year ended September 30 2026
Unaudited Financial Results For Quarter And Half Year Ended September 2026
05-Nov-2026 | Source : BSEUnaudited Financial Results for Quarter and half year ended September 30 2026 along with the limited review report from the Statutory Auditor.
Board Meeting Outcome for Outcome Of Board Meeting
05-Nov-2026 | Source : BSEOutcome of Board Meeting
Corporate Actions
No Upcoming Board Meetings
Titan Biotech Ltd has declared 25% dividend, ex-date: 22 Sep 26
Titan Biotech Ltd has announced 2:10 stock split, ex-date: 20 Feb 26
Titan Biotech Ltd has announced 1:4 bonus issue, ex-date: 23 Oct 26
No Rights history available